Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacologic Agents Used to Reverse the Anticoagulant Effect of Common Anticoagulants.

Southern medical journal·2022

Same author

A Brief Review of the Pharmacology of Hyperkalemia: Causes and Treatment.

Southern medical journal·2019

Same author

A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions.

Southern medical journal·2018

Same author

Commentary on "Therapeutic Error Calls Among Older Adults Reported to a Regional Poison Control Center in Alabama".

Southern medical journal·2016

Same author

SMJ Response.

Southern medical journal·2015

Same author

Commentary on "Antithrombotic Therapy Practices in Older Adults Residing in the Long-Term Care Setting".

Southern medical journal·2015

Search research articles

Related Experiment Video

Updated: May 16, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Comparing new anticoagulants.

James M Wooten¹

¹University of Missouri-Kansas City School of Medicine, Kansas City, MO 64108, USA. wootenj@umkc.edu

Southern Medical Journal

|December 6, 2012

Summary

New anticoagulant drugs, dabigatran and rivaroxaban, offer alternatives to warfarin. Patient monitoring remains crucial, as warfarin may still be preferred for certain individuals.

Area of Science:

Pharmacology and Therapeutics
Cardiovascular Medicine

Background:

Warfarin, an effective anticoagulant, requires careful patient monitoring due to its pharmacology and risk profile.
The pharmaceutical industry seeks safer and more effective alternatives to warfarin.
Direct-to-consumer marketing has increased patient inquiries about new anticoagulants.

Purpose of the Study:

To review available data comparing new anticoagulants (dabigatran, rivaroxaban) with warfarin.
To inform physicians about the comparative efficacy and safety of these medications.

Main Methods:

Review of clinical data for dabigatran and rivaroxaban.
Comparison of these new drugs against warfarin for specific indications.

Main Results:

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: May 16, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Dabigatran and rivaroxaban have been approved by the FDA.
These new drugs present potential benefits and alternatives to warfarin for some patients.
Warfarin may remain the optimal choice for other patient populations.

Conclusions:

Dabigatran and rivaroxaban represent significant advancements in anticoagulant therapy.
The choice between warfarin and newer agents depends on individual patient factors and clinical indications.
Physician guidance is essential in selecting the most appropriate anticoagulant.